Aruvant

Aruvant Sciences is a private clinical-stage gene therapy company focused on developing and commercializing transformative therapies for patients with severe hematological conditions. The company’s near-term focus is on sickle cell disease, with a subsequent expansion into β-thalassemia. Aruvant’s lead candidate, ARU-1801, consists of autologous cells that are genetically modified with a lentiviral vector that encodes a novel, highly potent, anti-sickling γ-globin. ARU-1801 was designed to address the limitations of current curative treatment options, such as low donor availability and the need for more toxic, intensive chemotherapy conditioning regimens for stem cell transplants.